These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26008804)

  • 21. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
    Bays HE; Sartipy P; Xu J; Sjöström CD; Underberg JA
    J Clin Lipidol; 2017; 11(2):450-458.e1. PubMed ID: 28502502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dapagliflozin on cardiovascular risk factors.
    Ptaszynska A; Hardy E; Johnsson E; Parikh S; List J
    Postgrad Med; 2013 May; 125(3):181-9. PubMed ID: 23748519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.
    Rizzo M; Al-Busaidi N; Rizvi AA
    Expert Opin Pharmacother; 2015 Feb; 16(3):281-4. PubMed ID: 25516459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
    Cahn A; Mosenzon O; Wiviott SD; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Diabetes Care; 2020 Feb; 43(2):468-475. PubMed ID: 31843945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
    Weir MR; Januszewicz A; Gilbert RE; Vijapurkar U; Kline I; Fung A; Meininger G
    J Clin Hypertens (Greenwich); 2014 Dec; 16(12):875-82. PubMed ID: 25329038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
    Leiter LA; Cefalu WT; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
    J Am Geriatr Soc; 2014 Jul; 62(7):1252-62. PubMed ID: 24890683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
    Sonesson C; Johansson PA; Johnsson E; Gause-Nilsson I
    Cardiovasc Diabetol; 2016 Feb; 15():37. PubMed ID: 26895767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
    Chilton R; Tikkanen I; Hehnke U; Woerle HJ; Johansen OE
    Diabetes Obes Metab; 2017 Nov; 19(11):1620-1624. PubMed ID: 28387058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
    Petrykiv SI; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2017 Oct; 19(10):1363-1370. PubMed ID: 28295959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.
    Fadini GP; Solini A; Manca ML; Penno G; Gatti A; Anichini R; Del Prato S; Avogaro A;
    Diabetes Obes Metab; 2019 Feb; 21(2):252-260. PubMed ID: 30136354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
    Iacobellis G; Gra-Menendez S
    Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
    Johnsson K; Johnsson E; Mansfield TA; Yavin Y; Ptaszynska A; Parikh SJ
    Postgrad Med; 2016 May; 128(4):346-55. PubMed ID: 26878357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.